<div id="readability-page-1"><p>Oppenheimer analyst Leland Gershell reiterated a Buy rating on enGene Holdings today and set a price target of $33.00.</p><h3>Claim 70% Off TipRanks This Holiday Season</h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>Gershell covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Viridian Therapeutics, and Capricor Therapeutics. According to TipRanks, Gershell has an average return of <span>7.5%</span> and a 41.90% success rate on recommended stocks. </p> <p>In a report released today, Wells Fargo also maintained a Buy rating on the stock with a $25.00 price target.</p></div>

ENGN

<p>Oppenheimer analyst Leland Gershell reiterated a Buy rating on enGene Holdings with a $33.00 price target. Wells Fargo also maintained a Buy rating with a $25.00 target. Gershell, who covers the Healthcare sector, has an average return of 7.5% and a 41.90% success rate on recommended stocks.</p>

Oppenheimer Remains a Buy on enGene Holdings (ENGN)